Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
April 29, 2024 | Insights, US, healthcare, market research
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and client management. Throughout her career, Kathy has worked extensively at guiding her clients to identify the optimal research approach to address the business issue at hand. In Kathy’s most recent position as Senior Vice President, Business Development at ThinkGen, she was responsible for implementing the business development and marketing strategy and overseeing all client outreach.
In 2023, Kathy was honored with the Healthcare Businesswomen’s Association (HBA) Luminary Award which recognizes professionals who have made a significant impact on the healthcare industry and have a proven track record of helping advance careers of other women. Kathy also volunteered as a HBA mentor as part of the HBA Mentoring Program.
In this pivotal role at Research Partnership, Kathy will be working with our Commercial Team to identify new business opportunities, nurture existing partnerships and enhance our US based presence in the market.
US President, Sue Wild commented “I am delighted to welcome Kathy to the team, she has extensive experience and will be instrumental in nurturing our client relationships in the US market. I look forward to collaborating with Kathy to strengthen our offerings in delivering the best possible insights for our valued clients”.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies…
AI without limits: A smarter, integrated approach to Medical Affairs
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless…
What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
AI with intent: How Inizio is redefining pharma through precision and partnership
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the…
Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.
Delivering purposeful solutions at Obesity Week 2025
We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.
Inizio strengthens executive team with new leadership appointments
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™…
Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across…
Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care
Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.
Inizio appoints Ryan Quigley as CEO
Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. …